Pharma, whistleblower lessons learned from $900M Biogen settlement
By 
Adrianne Appel2022-10-11T15:45:00
The high price on Biogen’s $900 million settlement for False Claims Act (FCA) violations shows the government is still keenly interested in cases of illegal kickbacks in physician referrals, experts and attorneys said.
“It’s a wake-up call to companies that they need to remain diligent in their compliance in this area,” said David Colapinto, partner at whistleblower law firm Kohn, Kohn & Colapinto.
Last month, Biogen finalized settlement of the lawsuit, after years of litigation by former employee Michael Bawduniak. Bawduniak, represented by boutique law firm Greene, alleged the company paid illegal kickbacks to doctors to induce them to prescribe Biogen’s multiple sclerosis drugs.
Related articles
-
News BriefSEC levies no fine against Kiromic BioPharma after material omissions self-disclosure
Kiromic BioPharma will pay no fine to the Securities and Exchange Commission after self-reporting that it failed to disclose material information about two cancer drugs to investors.
-
ArticleBiogen finalizes $900M settlement in false claims whistleblower suit
Biogen finalized a $900 million settlement concerning alleged kickbacks it paid to doctors to induce them to prescribe the company’s drugs and not those of its competitors.
-
ArticleEssilor agrees to $22M settlement over kickback charges
Essilor, a manufacturer and distributor of optical lenses and equipment, will pay $22 million to settle allegations it paid kickbacks to spur sales in violation of the False Claims Act.
More from Regulatory Enforcement
-
News BriefDOJ sues Uber over alleged discrimination against disabled riders
The DOJ sued Uber Thursday, alleging it violated the Americans with Disabilities Act (ADA) by denying people with disabilities equal access to its services.
-
ArticleEU targets crypto, fintech firms in push to tackle money laundering
Europe’s banking regulator warns that weak compliance at fintech, regtech, and crypto firms may let money laundering and terrorist financing risks slip through. The EBA also found EU regulators’ approaches are often inconsistent and unclear.
-
ArticleCalifornia, Colorado, and Connecticut launch joint crackdown on privacy violators
California, Colorado, and Connecticut launched a joint enforcement sweep against businesses that fail to honor consumers’ online opt-out requests, the states announced Tuesday.